JP2021522793A - ＴＧＦβスーパーファミリーリガンドの多特異性バインダーおよびその使用 - Google Patents

ＴＧＦβスーパーファミリーリガンドの多特異性バインダーおよびその使用 Download PDF

Info

Publication number
JP2021522793A
JP2021522793A JP2020561726A JP2020561726A JP2021522793A JP 2021522793 A JP2021522793 A JP 2021522793A JP 2020561726 A JP2020561726 A JP 2020561726A JP 2020561726 A JP2020561726 A JP 2020561726A JP 2021522793 A JP2021522793 A JP 2021522793A
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
polypeptide
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020561726A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021522793A5 (https=
JPWO2019213442A5 (https=
Inventor
ラビンドラ クマール，
ラビンドラ クマール，
ダイアン エス． サコ，
ダイアン エス． サコ，
ロズリーヌ カストンギー，
ロズリーヌ カストンギー，
ズー−シン クオ，
ズー−シン クオ，
Original Assignee
アクセルロン ファーマ インコーポレイテッド
アクセルロン ファーマ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アクセルロン ファーマ インコーポレイテッド, アクセルロン ファーマ インコーポレイテッド filed Critical アクセルロン ファーマ インコーポレイテッド
Publication of JP2021522793A publication Critical patent/JP2021522793A/ja
Publication of JP2021522793A5 publication Critical patent/JP2021522793A5/ja
Publication of JPWO2019213442A5 publication Critical patent/JPWO2019213442A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2020561726A 2018-05-03 2019-05-02 ＴＧＦβスーパーファミリーリガンドの多特異性バインダーおよびその使用 Pending JP2021522793A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862666547P 2018-05-03 2018-05-03
US62/666,547 2018-05-03
US201862779998P 2018-12-14 2018-12-14
US62/779,998 2018-12-14
PCT/US2019/030469 WO2019213442A1 (en) 2018-05-03 2019-05-02 MULTISPECIFIC BINDERS OF TGFβ-SUPERFAMILY LIGANDS AND USES THEREOF

Publications (3)

Publication Number Publication Date
JP2021522793A true JP2021522793A (ja) 2021-09-02
JP2021522793A5 JP2021522793A5 (https=) 2022-05-13
JPWO2019213442A5 JPWO2019213442A5 (https=) 2022-05-13

Family

ID=68386158

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020561726A Pending JP2021522793A (ja) 2018-05-03 2019-05-02 ＴＧＦβスーパーファミリーリガンドの多特異性バインダーおよびその使用

Country Status (6)

Country Link
US (2) US12103959B2 (https=)
EP (1) EP3788066A4 (https=)
JP (1) JP2021522793A (https=)
AU (1) AU2019262139A1 (https=)
CA (1) CA3099527A1 (https=)
WO (1) WO2019213442A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4073101A4 (en) * 2019-12-10 2024-01-10 Acceleron Pharma Inc. SINGLE-ARM ACTRIIA AND ACTRIIB HETEROMULTIMERS AND METHOD FOR TREATING PULMONARY HYPERTENSION
KR20230117348A (ko) * 2020-11-04 2023-08-08 에이치큐 한 Tgf-베타 계열의 다중 리간드를 저해할 수 있는 신규한 이작용성 다중특이적 길항제 및 이의 용도
US20240277807A1 (en) * 2021-06-11 2024-08-22 Acceleron Pharma Inc. Actrii proteins and uses thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013521311A (ja) * 2010-03-05 2013-06-10 ザ・ジョンズ・ホプキンス・ユニバーシティー 標的免疫調節抗体および融合タンパク質に基づく組成物および方法
JP2016037488A (ja) * 2014-08-11 2016-03-22 日本化薬株式会社 ＴＧＦβ阻害機能を持つキメラタンパク質
WO2016164089A2 (en) * 2015-04-06 2016-10-13 Acceleron Pharma Inc. Tgf-beta superfamily type i and type ii receptor heteromultimers and uses thereof
JP2017506217A (ja) * 2014-02-10 2017-03-02 メルク パテント ゲーエムベーハー 標的ＴＧＦβ阻害
WO2018009624A1 (en) * 2016-07-07 2018-01-11 Acceleron Pharma Inc. Tgf-beta superfamily heteromultimers and uses thereof
WO2018113185A1 (zh) * 2016-12-23 2018-06-28 深圳国人通信股份有限公司 一种介质移相器

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107849114B (zh) * 2015-04-06 2021-08-20 阿塞勒隆制药公司 单臂i型和ii型受体融合蛋白和其用途
JP7280182B2 (ja) 2016-10-05 2023-05-23 アクセルロン ファーマ インコーポレイテッド バリアントＡｃｔＲＩＩＢタンパク質およびその使用
US11440949B2 (en) * 2016-10-05 2022-09-13 Acceleron Pharma Inc. TGF-beta superfamily type I and type II receptor heteromultimers and uses thereof
CA3099325A1 (en) * 2018-05-03 2019-11-07 Acceleron Pharma Inc. Novel binders of tgf.beta.-superfamily ligands and uses thereof
EP3807308A4 (en) * 2018-06-15 2022-03-16 Acceleron Pharma Inc. BI AND TRIFUNCTIONAL FUSION PROTEINS AND THEIR USES

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013521311A (ja) * 2010-03-05 2013-06-10 ザ・ジョンズ・ホプキンス・ユニバーシティー 標的免疫調節抗体および融合タンパク質に基づく組成物および方法
JP2017506217A (ja) * 2014-02-10 2017-03-02 メルク パテント ゲーエムベーハー 標的ＴＧＦβ阻害
JP2016037488A (ja) * 2014-08-11 2016-03-22 日本化薬株式会社 ＴＧＦβ阻害機能を持つキメラタンパク質
WO2016164089A2 (en) * 2015-04-06 2016-10-13 Acceleron Pharma Inc. Tgf-beta superfamily type i and type ii receptor heteromultimers and uses thereof
WO2018009624A1 (en) * 2016-07-07 2018-01-11 Acceleron Pharma Inc. Tgf-beta superfamily heteromultimers and uses thereof
WO2018113185A1 (zh) * 2016-12-23 2018-06-28 深圳国人通信股份有限公司 一种介质移相器

Also Published As

Publication number Publication date
US20250109179A1 (en) 2025-04-03
AU2019262139A1 (en) 2020-11-26
WO2019213442A1 (en) 2019-11-07
US12103959B2 (en) 2024-10-01
EP3788066A1 (en) 2021-03-10
CA3099527A1 (en) 2019-11-07
US20220372107A1 (en) 2022-11-24
EP3788066A4 (en) 2022-01-26

Similar Documents

Publication Publication Date Title
JP7246618B2 (ja) ＡＬＫ７：ＡｃｔＲＩＩＢヘテロ多量体およびその使用
JP7055637B2 (ja) ＡＬＫ４：ＡｃｔＲＩＩＢヘテロ多量体およびその使用
JP7058606B2 (ja) 増加した免疫活性において使用するためのａｃｔｒｉｉアンタゴニスト
US9452197B2 (en) Antagonists of BMP9, BMP10, ALK1 and other ALK1 ligands, and uses thereof
JP7159148B2 (ja) Ｔｇｆベータスーパーファミリーホモ多量体およびその使用
JP2024113195A (ja) Ｔｇｆ－ベータスーパーファミリーｉ型およびｉｉ型受容体ヘテロ多量体ならびにその使用
US20250333477A1 (en) Novel binders of tgfb-superfamily ligands and uses thereof
KR20230079096A (ko) 항체-약물 접합체를 포함하는 약제학적 조성물 및 약제학적 조성물의 용도
US20250109179A1 (en) MULTISPECIFIC BINDERS OF TGFBeta-SUPERFAMILY LIGANDS AND USES THEREOF
JP2021526835A (ja) 二機能性および三機能性融合タンパク質およびその使用
JP2023528709A (ja) バリアントａｃｔｒｉｉｂタンパク質およびその使用
JPWO2018009624A5 (https=)
HK40093161A (zh) 抗ctla-4抗体药物组合物及其用途
CA3211515A1 (en) Actrii-alk4 antagonists and methods of treating heart failure
HK1248735B (en) Alk7:actriib heteromultimers and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220502

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220502

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20230221

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230330

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230418

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20231114